Determination of HLA-A,B residue mismatch acceptability for kidneys transplanted into highly sensitized patients: A report of a collaborative study conducted during the 12th International Histocompatibility Workshop

Transplantation

Volumn 63, Issue 12, 1997, Pages 1743-1751

  Duquesnoy, Rene J ^a,b   Marrari, Marilyn ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIBODY; HLA A ANTIGEN; HLA B ANTIGEN; IMMUNOGLOBULIN ANTIBODY;

ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY TEST; GRAFT SURVIVAL; HLA MATCHING; HUMAN; KIDNEY ALLOGRAFT; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SERUM;

ANTIBODY SPECIFICITY; FEMALE; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; INTERNATIONAL COOPERATION; KIDNEY TRANSPLANTATION; LABORATORIES; MALE; QUALITY CONTROL; TREATMENT OUTCOME;

EID: 0030996544     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199706270-00007     Document Type: Article

References (51)

1. Oldfather JW, Anderson CB, Phelan DL, et al. Prediction of crossmatch outcome in highly sensitized dialysis patients based on the identification of serum HLA antibodies. Transplantation 1986; 43: 267.
2. Delmonico FL, Fuller A, Cosimi AB, et al. New approaches to donor crossmatching and successful transplantation of highly sensitized patients. Transplantation 1983; 36: 629.
3. Duquesnoy RJ, White LT, Fierst JW, et al. Multiscreen serum analysis of highly sensitized renal dialysis patients for antibodies toward public and private class I HLA determinants: implications for computer-predicted acceptable and unacceptable donor mismatches in kidney transplantation. Transplantation 1990; 50: 427.
4. Rodey GE, Neylan JF, Whelchel JD, Revels KW, Bray RA. Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol 1994; 39: 272.
5. Rodey GE, Fuller TC. Public epitopes and the antigenic structure of the HLA molecules. Crit Rev Immunol 1987; 7: 229.
6. Fuller A, Trevithick J, Rodey G, Parham P, Fuller T. Topographic map of the HLA-A2 CREG epitopes using human alloantibody probes. Hum Immunol 1990; 28: 284.
7. Fuller A, Rodey G, Parham P, Fuller T. Epitope map of the HLA-B7CREG using affinity-purified human alloantibody probes. Hum Immunol 1990; 28: 306.
8. Laundy GJ, Bradley BA. The predictive value of epitope analysis in highly sensitized patients awaiting renal transplantation. Transplantation 1995; 59: 1207.
9. Hildebrand WH, Madrigal JA, Little AM, Parham P. HLA-Bw22: a family of molecules with identity to HLA-B7 in the alpha 1-helix. J Immunol 1992; 148: 1155.
10. Hildebrand WH, Madrigal JA, Belich MP, et al. Serologic cross-reactivities poorly reflect allelic relationships in the HLA-B12 and HLA-B21 groups: dominant epitopes of the alpha 2 helix. J Immunol 1992; 149: 3563.
11. Madrigal JA, Hildebrand WH, Belich MP, et al. Structural diversity in the HLA-A10 family of alleles: correlations with serology. Tissue Antigens 1993; 41: 72.
12. DeVito LD, Hogan KT, Mason BP, et al. Epitope fine specificity of human anti-HLA-A2 antibodies. Transplant Proc 1993; 25: 189.
13. Lutz CT, Smith KD, Greazel NS, et al. Bw4-reactive and Bw6-reactive antibodies recognize multiple distinct HLA structures that partially overlap in the alpha-1 helix. J Immunol 1994; 153: 4099.
14. Turka L, Goguen J, Gagne J, Milford E. Presensitization and the renal allograft recipient. Transplantation 1989; 47: 234.
15. Thick M, Turner R, Welsh K, Taube D. An expert system for the difficult renal crossmatch. Transplant Proc 1989; 21: 719.
16. Opelz G. Collaborative Transplant Study Kidney Exchange Trial for highly sensitized recipients. In: Terasaki PI, Cecka JM. Clinical transplants 1990. Los Angeles: UCLA Tissue Typing Laboratory, 1991: 61.
17. Thompson JS, Bryne JE, Hempel HO, et al. Computer algorithm that predicts both acceptable and unacceptable private and public HLA class I antigens in highly sensitized patients. Transplant Proc 1993; 25: 251.
18. van Rood JJ, Lagaaij EL, Doxiadis I, Roelen D, Persijn G, Claas F. Permissible mismatches, acceptable mismatches, and tolerance: new trends in decision making. In: Terasaki PI, Cecka JM. Clinical transplants 1992. Los Angeles: UCLA Tissue Typing Laboratory, 1993: 285.
19. Oldfather J, Mora A, Phelan D, et al. The occurrence of cross-reactive "public" antibodies in the sera of highly sensitized dialysis patients. Transplant Proc 1983; 15: 1212.
20. Rodey G, Fuller T, Amos B, et al. Preliminary report of the American Society for Histocompatibility and Immunogenetics phase I workshop on HKLA class I public epitopes. Transplant Proc 1987; 19: 872.
21. Bjorkman P, Parham P. Class I MHC molecules. Annu Rev Biochem 1990; 59: 253.
22. Duquesnoy R, Marrari M. Antibody specificity analysis of sera from highly sensitized patients: identification of unacceptable HLA class I mismatches and its clinical relevance to transplant outcome. In: Charron D, ed. Genetic diversity of HLA: functional and medical implications. Proceedings of the 12th International Histocompatibility Workshop, vol 1. Sèvres, France: EDK Publishers, (in press).
23. Fuller T, Cosimi A, Russell P, et al. Use of an antiglobulin-ATG reagent for detection of low levels of alloantibody: improvement of allograft survival in presensitized recipients. Transplant Proc 1978; 10: 463.
24. Daily OP: Annual Report of the US Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network. Richmond, VA: UNOS, 1994.
25. Paul L, Baldwin W, van Es L. Vascular endothelial antigens in renal transplantation. Transplantation 1985; 40: 117.
26. Cerilli J, Brasile L, Galouzis T, Lempert N, Clarke J. The vascular endothelial cell antigen system. Transplantation 1985; 39: 286.
27. Moraes J, Moraes M, Luo Y, Stastny P. Alloantibodies against donor epidermis and early kidney transplant rejection. Transplantation 1991; 51: 370.
28. Baldwin W, Pruitt S, Sanfilippo F. Alloantibodies: basic and clinical concepts. Transplant Rev 1991; 5: 100.
29. Harmer A, Haskard D, Koffman C, Welsh K. Novel antibodies associated with unexplained loss of renal allografts. Transpl Int 1990; 3: 66.
30. Chapman J, Taylor C, Ting A, Morris P. Immunoglobulin class and specificity of antibodies causing positive T cell crossmatches. Transplantation 1986; 42: 608.
31. Mohanakumar T, Rhodes C, Mendez-Picon G, Goldman M, Lee H. Renal allograft rejection associated with presensitization to HLA-DR antigens. Transplantation 1981; 31: 93.
32. Scornik J, Lefor W, Cicciarelli J, et al. Hyperacute and acute kidney graft rejection associated with antibodies to B cells. Transplantation 1992; 54: 61.
33. Zhang L, van Bree S, Gijbels Y, van Veen A, van Rood JJ, Claas FH. Comparison of the humoral and cytotoxic T-lymphocyte response to individual HLA class I alloantigens in highly immunized patients. Hum Immunol 1991; 30: 156.
34. Roelen D, Datema G, Bree SV, Zhang L, van Rood J, Claas F. Evidence that antibody formation against a certain HLA alloantigen is associated not with a quantitative but a qualitative change in the cytotoxic T cells recognizing the same antigen. Transplantation 1992; 53: 899.
35. Grimm PC, Ettenger RB. High cellular anti-HLA immune responsiveness accompanies the highly sensitized (high PRA) state in dialysis patients. Transplant Proc 1991; 23: 405.
36. Kato K, Trapani J, Allopenna J, Dupont B, Yang S. Molecular analysis of the serologically defined HLA-Aw19 antigens: a genetically distinct family of HLA-A antigens comprising A29, A31 A32 and A33, but probably not A30. J Immunol 1989; 143: 3371.
37. Salter R, Parham P. Mutually exclusive public epitopes of HLA-A,B,C molecules. Hum Immunol 1989; 26: 85.
38. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. The role of HLA typing in clinical kidney transplants, 30 years later: indisputable fact regarding clinical organ transplantation [Editorial]. In: Terasaki PI, Cecka JM. Clinical transplants 1992. Los Angeles: UCLA Tissue Typing Laboratory, 1993: 442.
39. Terasaki PI, Takemoto S, Park MS, Clark BD. HLA epitope matching. Transfusion 1992; 32: 775.
40. Takemoto S, Gjertson DW, Terasaki PI. HLA matching: a comparison of conventional and molecular approaches. In: Terasaki PI, Cecka JM. Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1992: 413.
41. Parham P. Of Payne, polymorphism, and populations [Review]. Hum Immunol 1994; 40: 77.
42. Charron D, ed. Genetic diversity of HLA: functional and medical implications. Proceedings of the 12th International Histocompatibility Workshop, vol 1. Sèvres, France: EDK Publishers (in press).
43. Cardella C, Nicholson M, Falk J, Harding M, Cook G. Successful renal transplantation in patients with T-cell reactivity to donor. Lancet 1982; 2: 1240.
44. Cardella C, Falk J, Halloran P, Robinette M, Arbus G, Bear R. Renal transplantation in patients with a positive crossmatch on non-current sera: long-term follow-up. Transplant Proc 1985; 17: 626.
45. Schweizer R, Bow L. Successful kidney transplantation after loss of specific antidonor HLA antibodies. Transplantation 1983; 36: 731.
46. Matas A, Nehlsen-Cannarella S, Tellis V, Kuemmel P, Soberman R, Veith F. Successful kidney transplantation with current seranegative/historical sera-positive T cell crossmatch. Transplantation 1984; 37: 111.
47. Goeken N. Outcome of renal transplantation following a positive cross-match with historical sera. Hum Immunol 1984; 14: 77
48. Kerman R, Flechner S, vanBuren C, Lorber M, Kahan B. Successful transplantation of cyclosporine-treated allograft recipients with serologically positive historical, but negative preoperative donor crossmatches. Transplantation 1985; 40: 615.
49. Reed E, Hardy M, Benvenisty A, et al. Effect of anti-idiotypic antibodies to HLA on graft survival in renal transplant recipients. N Engl J Med 1987; 316: 1450.
50. Rodey GE, Phelan DL. Association of antiidiotypic antibody with successful second transplant of a kidney sharing HLA antigens with the previous hyperacutely rejected first kidney. Transplantation 1989; 48: 54.
51. Suciu-Foca N, Reed E, D'Agati VD, et al. Soluble HLA antigens, anti-HLA antibodies and anti-idiotypic antibodies in the circulation of renal transplant recipients. Transplantation 1991; 51: 593.